RyanT2021
2021-11-26
Hooray
Roche shareholders approve deal to buy Novartis's $20.7 billion stake<blockquote>罗氏股东批准收购诺华207亿美元股份的交易</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
6
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":877689986,"tweetId":"877689986","gmtCreate":1637924331182,"gmtModify":1637924331182,"author":{"id":3584238171442752,"idStr":"3584238171442752","authorId":3584238171442752,"authorIdStr":"3584238171442752","name":"RyanT2021","avatar":"https://static.tigerbbs.com/c3aa70ae67b23e62ebdede4c992de8f8","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Hooray</p></body></html>","htmlText":"<html><head></head><body><p>Hooray</p></body></html>","text":"Hooray","highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/877689986","repostId":1190474385,"repostType":4,"repost":{"id":"1190474385","kind":"news","pubTimestamp":1637924231,"share":"https://www.laohu8.com/m/news/1190474385?lang=zh_CN&edition=full","pubTime":"2021-11-26 18:57","market":"us","language":"en","title":"Roche shareholders approve deal to buy Novartis's $20.7 billion stake<blockquote>罗氏股东批准收购诺华207亿美元股份的交易</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1190474385","media":"Reuters","summary":"ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion de","content":"<p>ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.</p><p><blockquote>苏黎世（路透社）-瑞士制药商罗氏表示，周五，罗氏股东以压倒性多数投票支持以207亿美元收购诺华近三分之一投票权股份的交易。</blockquote></p><p> Roche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades.</p><p><blockquote>罗氏召开了一次特别股东大会，以解决与两家总部位于巴塞尔的制药公司脱钩的计划相关的问题，这两家公司因这项投资而联系了二十年。</blockquote></p><p> Shareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.</p><p><blockquote>罗氏表示，股东以100.00%的多数票批准了公司截至2021年10月31日经审计的法定中期财务报表。</blockquote></p><p> They also backed the plan to cancel the 53.3 million shares bought, with a majority of 99.85%.</p><p><blockquote>他们还以99.85%的多数票支持取消购买的5330万股股票的计划。</blockquote></p><p> Therefore, the corporate law requirements for the repurchase have been satisfied, Roche said. The closing of the repurchase transaction is expected to take place in early December 2021.</p><p><blockquote>罗氏表示，因此，回购的公司法要求已经得到满足。回购交易预计将于2021年12月初完成。</blockquote></p><p> \"Today's resolutions of the Extraordinary General Meeting are in the best economic and strategic interest of Roche,\" said Roche Chairman Christoph Franz. \"As a result, we will be even better positioned to make a contribution to the health of people around the world.\"</p><p><blockquote>罗氏董事长Christoph Franz表示：“今天临时股东大会的决议符合罗氏的最佳经济和战略利益。”“因此，我们将能够更好地为世界各地人民的健康做出贡献。”</blockquote></p><p> Novartis agreed earlier this month to sell 53.3 million Roche bearer shares for $388.99 (356.93 Swiss francs) per share, a price that reflected the volume-weighted average of the Roche non-voting equity certificates over the 20 trading days to Nov. 2.</p><p><blockquote>诺华本月早些时候同意以每股388.99美元（356.93瑞士法郎）的价格出售5330万股罗氏无记名股票，该价格反映了截至11月2日的20个交易日罗氏无投票权股票的成交量加权平均值。</blockquote></p><p> The repurchase was conditional upon the approval by shareholders of a capital reduction by cancellation of the repurchased shares and of the interim financial statements prepared for the transaction.</p><p><blockquote>购回须待股东批准通过注销购回股份削减股本及就交易编制的中期财务报表后方可作实。</blockquote></p><p> Novartis' involvement started in 2001, when Swiss activist investor Martin Ebner, known for orchestrating the merger that created banking giant UBS, offered his Roche stake to its cross-town rival out of frustration over rebuffed proposals.</p><p><blockquote>诺华的参与始于2001年，当时瑞士激进投资者马丁·埃布纳(Martin Ebner)因策划了创建银行业巨头瑞银(UBS)的合并而闻名，出于对被拒绝的提议的沮丧，他将自己持有的罗氏股份提供给了其同城竞争对手。</blockquote></p><p> Roche Chairman Franz said earlier this month that the deal would give his company more strategic flexibility, as Roche could now make plans without needing the approval of Novartis.</p><p><blockquote>罗氏董事长弗朗兹本月早些时候表示，这笔交易将使他的公司在战略上有更大的灵活性，因为罗氏现在可以制定计划，而不需要诺华的批准。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche shareholders approve deal to buy Novartis's $20.7 billion stake<blockquote>罗氏股东批准收购诺华207亿美元股份的交易</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche shareholders approve deal to buy Novartis's $20.7 billion stake<blockquote>罗氏股东批准收购诺华207亿美元股份的交易</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-26 18:57</span>\n</p>\n</h4>\n</header>\n<article>\n<p>ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.</p><p><blockquote>苏黎世（路透社）-瑞士制药商罗氏表示，周五，罗氏股东以压倒性多数投票支持以207亿美元收购诺华近三分之一投票权股份的交易。</blockquote></p><p> Roche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades.</p><p><blockquote>罗氏召开了一次特别股东大会，以解决与两家总部位于巴塞尔的制药公司脱钩的计划相关的问题，这两家公司因这项投资而联系了二十年。</blockquote></p><p> Shareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.</p><p><blockquote>罗氏表示，股东以100.00%的多数票批准了公司截至2021年10月31日经审计的法定中期财务报表。</blockquote></p><p> They also backed the plan to cancel the 53.3 million shares bought, with a majority of 99.85%.</p><p><blockquote>他们还以99.85%的多数票支持取消购买的5330万股股票的计划。</blockquote></p><p> Therefore, the corporate law requirements for the repurchase have been satisfied, Roche said. The closing of the repurchase transaction is expected to take place in early December 2021.</p><p><blockquote>罗氏表示，因此，回购的公司法要求已经得到满足。回购交易预计将于2021年12月初完成。</blockquote></p><p> \"Today's resolutions of the Extraordinary General Meeting are in the best economic and strategic interest of Roche,\" said Roche Chairman Christoph Franz. \"As a result, we will be even better positioned to make a contribution to the health of people around the world.\"</p><p><blockquote>罗氏董事长Christoph Franz表示：“今天临时股东大会的决议符合罗氏的最佳经济和战略利益。”“因此，我们将能够更好地为世界各地人民的健康做出贡献。”</blockquote></p><p> Novartis agreed earlier this month to sell 53.3 million Roche bearer shares for $388.99 (356.93 Swiss francs) per share, a price that reflected the volume-weighted average of the Roche non-voting equity certificates over the 20 trading days to Nov. 2.</p><p><blockquote>诺华本月早些时候同意以每股388.99美元（356.93瑞士法郎）的价格出售5330万股罗氏无记名股票，该价格反映了截至11月2日的20个交易日罗氏无投票权股票的成交量加权平均值。</blockquote></p><p> The repurchase was conditional upon the approval by shareholders of a capital reduction by cancellation of the repurchased shares and of the interim financial statements prepared for the transaction.</p><p><blockquote>购回须待股东批准通过注销购回股份削减股本及就交易编制的中期财务报表后方可作实。</blockquote></p><p> Novartis' involvement started in 2001, when Swiss activist investor Martin Ebner, known for orchestrating the merger that created banking giant UBS, offered his Roche stake to its cross-town rival out of frustration over rebuffed proposals.</p><p><blockquote>诺华的参与始于2001年，当时瑞士激进投资者马丁·埃布纳(Martin Ebner)因策划了创建银行业巨头瑞银(UBS)的合并而闻名，出于对被拒绝的提议的沮丧，他将自己持有的罗氏股份提供给了其同城竞争对手。</blockquote></p><p> Roche Chairman Franz said earlier this month that the deal would give his company more strategic flexibility, as Roche could now make plans without needing the approval of Novartis.</p><p><blockquote>罗氏董事长弗朗兹本月早些时候表示，这笔交易将使他的公司在战略上有更大的灵活性，因为罗氏现在可以制定计划，而不需要诺华的批准。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RHHBY":"罗氏控股","NVS":"诺华"},"source_url":"https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190474385","content_text":"ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.\nRoche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades.\nShareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.\nThey also backed the plan to cancel the 53.3 million shares bought, with a majority of 99.85%.\nTherefore, the corporate law requirements for the repurchase have been satisfied, Roche said. The closing of the repurchase transaction is expected to take place in early December 2021.\n\"Today's resolutions of the Extraordinary General Meeting are in the best economic and strategic interest of Roche,\" said Roche Chairman Christoph Franz. \"As a result, we will be even better positioned to make a contribution to the health of people around the world.\"\nNovartis agreed earlier this month to sell 53.3 million Roche bearer shares for $388.99 (356.93 Swiss francs) per share, a price that reflected the volume-weighted average of the Roche non-voting equity certificates over the 20 trading days to Nov. 2.\nThe repurchase was conditional upon the approval by shareholders of a capital reduction by cancellation of the repurchased shares and of the interim financial statements prepared for the transaction.\nNovartis' involvement started in 2001, when Swiss activist investor Martin Ebner, known for orchestrating the merger that created banking giant UBS, offered his Roche stake to its cross-town rival out of frustration over rebuffed proposals.\nRoche Chairman Franz said earlier this month that the deal would give his company more strategic flexibility, as Roche could now make plans without needing the approval of Novartis.","news_type":1,"symbols_score_info":{"NVS":0.9,"RHHBY":0.9}},"isVote":1,"tweetType":1,"viewCount":2985,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":6,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/877689986"}
精彩评论